|
ARL5B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.73589999544299E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.49039999999923E-05 |
| Normal-vs-Stage2 |
1.71569999996013E-06 |
| Normal-vs-Stage3 |
5.3290000001649E-07 |
| Normal-vs-Stage4 |
4.09720000038583E-07 |
| Stage1-vs-Stage2 |
7.497900E-02 |
| Stage1-vs-Stage3 |
4.977600E-02 |
| Stage1-vs-Stage4 |
3.371900E-02 |
| Stage2-vs-Stage3 |
8.257400E-01 |
| Stage2-vs-Stage4 |
9.613800E-01 |
| Stage3-vs-Stage4 |
7.722200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.635799999957E-06 |
| Normal-vs-AfricanAmerican |
1.035670E-02 |
| Normal-vs-Asian |
8.79679999954419E-07 |
| Caucasian-vs-AfricanAmerican |
7.740400E-01 |
| Caucasian-vs-Asian |
7.511700E-02 |
| AfricanAmerican-vs-Asian |
1.426610E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.80720000262514E-08 |
| Normal-vs-Female |
1.72779999996209E-06 |
| Male-vs-Female |
1.026060E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.94600000000312E-05 |
| Normal-vs-Age(41-60Yrs) |
3.1214999995921E-07 |
| Normal-vs-Age(61-80Yrs) |
2.20360000025011E-07 |
| Normal-vs-Age(81-100Yrs) |
5.416100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.075700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.820200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.912400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.597200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.352200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.683200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.124400E-02 |
| Classical-VS-Follicular |
7.824400E-02 |
| Classical-VS-Other |
2.620400E-01 |
| Classical-VS-Normal |
8.19980000000831E-05 |
| Tall-VS-Follicular |
8.285400E-01 |
| Tall-VS-Other |
7.605200E-01 |
| Tall-VS-Normal |
9.0779999994961E-07 |
| Follicular-VS-Other |
6.580000E-01 |
| Follicular-VS-Normal |
1.77329999999642E-05 |
| Other-VS-Normal |
1.285920E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.0839999997625E-07 |
| Normal-vs-N1 |
5.93489999999308E-05 |
| N0-vs-N1 |
3.082400E-01 |
|
|
